Page last updated: 2024-09-03

gefitinib and semaxinib

gefitinib has been researched along with semaxinib in 8 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(semaxinib)
Trials
(semaxinib)
Recent Studies (post-2010) (semaxinib)
5,2315662,91948031218

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)semaxinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Dihydrofolate reductaseHomo sapiens (human)2.4
Dihydrofolate reductaseMus musculus (house mouse)2.4
Epidermal growth factor receptorHomo sapiens (human)3.592
Platelet-derived growth factor receptor betaMus musculus (house mouse)4.05
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.084
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.17
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)0.5
Platelet-derived growth factor receptor betaHomo sapiens (human)2.3563
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.365
Fibroblast growth factor receptor 1Homo sapiens (human)4.865
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)0.5
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)3.89
Dihydrofolate reductasePneumocystis carinii2.4
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.7648
Fibroblast growth factor receptor 2Homo sapiens (human)5
Fibroblast growth factor receptor 4Homo sapiens (human)5
Fibroblast growth factor receptor 3Homo sapiens (human)5
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)4.05
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.275
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)1.04
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.0999
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)1.04
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.16
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.2
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)0.068
1,25-dihydroxyvitamin D-3 receptor Sus scrofa domesticus (domestic pig)1.04
Dihydrofolate reductaseRattus norvegicus (Norway rat)2.4
ALK tyrosine kinase receptorHomo sapiens (human)1.505

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Arlot, Y; Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bocci, G; Cosconati, S; D'Ocon, P; Da Settimo, F; Dalla Via, L; Fioravanti, A; Fornaciari, G; García-Argáez, AN; Gia, O; La Motta, C; Marini, AM; Novellino, E; Orlandi, P; Salerno, S; Sartini, S; Simorini, F; Taliani, S1
Kuwano, M; Ono, M1
Garber, K1
Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A1
Broxterman, HJ; Georgopapadakou, NH1

Reviews

1 review(s) available for gefitinib and semaxinib

ArticleYear
[Tumor angiogenesis and tumor angiogenesis inhibitors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

    Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1

2001

Other Studies

7 other study(ies) available for gefitinib and semaxinib

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Journal of enzyme inhibition and medicinal chemistry, 2010, Volume: 25, Issue:2

    Topics: Amides; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Urea; Vascular Endothelial Growth Factor Receptor-2

2010
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    European journal of medicinal chemistry, 2015, Oct-20, Volume: 103

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrans; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2015
Synthetic lethality: killing cancer with cancer.
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins

2002
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
    Il Giornale di chirurgia, 2003, Volume: 24, Issue:4

    Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors

2003
New cancer therapeutics: target-specific in, cytotoxics out?
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib

2004